FY2027 Earnings Estimate for BSX Issued By Erste Group Bank

Boston Scientific Corporation (NYSE:BSX) – Equities researchers at Erste Group Bank dropped their FY2027 earnings per share (EPS) estimates for shares of Boston Scientific in a report released on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the medical equipment provider will post earnings per share of $3.91 for the year, down from their prior forecast of $3.92. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the business earned $0.70 EPS. The company’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Several other brokerages have also recently commented on BSX. Robert W. Baird decreased their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Barclays cut their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. Truist Financial reduced their price target on Boston Scientific from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Finally, Royal Bank Of Canada decreased their price target on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $106.00.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $69.21 on Thursday. Boston Scientific has a 52 week low of $67.56 and a 52 week high of $109.50. The business’s 50 day moving average price is $77.45 and its 200 day moving average price is $90.83. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a market cap of $102.86 billion, a P/E ratio of 35.68, a P/E/G ratio of 1.08 and a beta of 0.69.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Steph & Co. acquired a new position in Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Finally, Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter worth about $26,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by company insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.